204.66
[1]. A O Ferreiro, et al. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc. 20 Dec;46(10):46-501.
[2]. Aleksandra Kezic, et al. Effects of everolimus on oxidative stress in kidney model of ischemia/reperfusion injury. Am J Nephrol. 201;7(4):21-01.
[]. Chang-Kwon Oh, et al. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Transplantation. 2015 Jan;(1):180-6.
[4]. Daniel J Inglis, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 20;15(11):1552-60.
[5]. Dorien Van den Bossche, et al. Deproteination of whole blood for LC-MS/MS using paramagnetic micro-particles. Clin Biochem. 20 Oct;47(15):112-5.
H51-H61-H7-H410
P260-P27-P280-P1-P405-P501
GHS08,GHS0
077